Electrocardiography (ECG) data collected by iRhythm Technologies Inc.'s Zio ambulatory continuous-care wearable ECG monitor can be analyzed by a “deep learning” artificial intelligence model to detect cardiac arrhythmias as effectively as a panel of expert cardiologists across 12 kinds of cardiac rhythm outputs, according to the results of a 53,549-patient trial.
iRhythm Builds Momentum Following Large Trial Of AI Approach To ECG Analysis
Results from a study of more than 91,000 ECG records collected with iRhythm’s Zio ambulatory continuous cardiac monitoring device that demonstrates the successful application of artificial intelligence to ECGs gives the 12-year-old company confidence that it will be profitable very soon.
More from Business
• By
Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.
• By
OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.
• By
Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.
• By
As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.
More from Medtech Insight
• By
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.
• By
The US FDA continues to issue early alerts as part of its communications pilot aimed at improving how the agency manages recalls. This time, the agency is notifying users about two separate intravascular catheters.
• By
The US Medicare agency will hold three public meetings in June and July addressing tremor treatment devices and clinical diagnostic lab tests. The first meeting on June 25 will focus on endpoints for Parkinson’s device trials, while subsequent meetings will address payment rates and codes for laboratory tests.